FINWIRES · TerminalLIVE
FINWIRES

Oil Surge, Trade Headwinds Bear Down on China Shares; Jiangxi Redboard Technology Falls 6%

By

Chinese shares closed lower on Friday as investors weighed escalating Middle East tensions, fresh U.S. tariffs and new defense restrictions against Beijing.

The Shanghai Composite Index, the main gauge of Chinese stocks, closed 1.6% lower to 3,814.20. The Shenzhen Component Index fell 2.5% to 13,774.68.

Oil prices pierced the $100-per-barrel threshold for the first time since May, following attacks by Yemen's Houthi rebels on Saudi vessels in the Red Sea. The U.S. military also carried out its 13th consecutive night of airstrikes against Iranian targets, with President Donald Trump indicating he is not yet prepared to re-enter ceasefire negotiations with Tehran.

Adding to the pressure, the Trump administration rolled out new tariffs of up to 12.5% on imports from several trading partners, citing forced labor concerns. Beijing was hit with a flat 12.5% levy on all goods.

Also, U.S. lawmakers advanced a defense legislation blocking the military from deploying humanoid robots made in China. Under Section 163 of the National Defense Authorization Act, the Pentagon is barred from procuring and using humanoid robotic systems produced, developed or controlled by adversarial nations, including China.

In company news, Jiangxi Redboard Technology (SHA:603459) subsidiary Ganzhou Redboard Technology will invest 5 billion yuan for the construction of a high-end mSAP or modified semi-additive process precision circuit board project. The company will also invest 700 million yuan to expand its high-density interconnect production lines and 300 million yuan to build a new standardized production plant and auxiliary facilities. Shares of the printed circuit board manufacturer fell 6% Friday.

Related Articles

Asia

Sichuan Biokin Pharmaceutical's ADC Enters Phase Three Trial for Biliary Tract Cancer

Sichuan Biokin Pharmaceutical (SHA:688506) said the first patient for its third-phase randomized controlled clinical trial has been dosed, according to a Friday filing with the Shanghai bourse.The trial is evaluating the company's flagship EGFR×HER3 bispecific antibody drug conjugate (ADC), Lunka Yilong Tuodan/Yizekang, for locally advanced or metastatic biliary tract cancer after platinum chemotherapy failure.Shares of the pharmaceutical company were down 4% in recent trade.

SHA:688506
Asia

Tcm Biotech's Safety Trial for UTI Drug to Continue After Review

Tcm Biotech International (TPE:4169) said an independent review of the interim analysis for its Phase three trial of U101, an oral drug candidate to prevent recurrent urinary tract infections in women, recommended the study continue as planned.The Independent Data Monitoring Committee found the trial's overall safety profile to be sound and recommended continuing patient enrollment, according to a Thursday Taiwan Exchange filing.The company did not disclose efficacy or statistical results, in line with the trial protocol.The trial aims to enroll 348 women, and is assessing U101's ability to prevent recurrent urinary tract infections over a 24-week treatment period.

TPE:4169
Asia

Market Chatter: Indian Billionaire Gautam Adani Considers Entering Airline Business

The group of Gautam Adani is considering launching a new airline, Reuters reported Thursday, citing two sources with direct knowledge of the matter.The report said no final decision has been made, with the group still evaluating the proposal given the challenges of generating profits in the airline industry.The Indian government has privately encouraged several business groups, including Adani, to consider starting an airline as Air India dealt with the aftermath of last year's fatal Ahmedabad crash and IndiGo faced operational disruptions, according to the report.Adani Enterprises (NSE:ADANIENT, BOM:512599), the Indian billionaire's flagship company, did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

BOM:512599NSE:ADANIENT